Você procurou por: timepoint (Inglês - Maltês)

timepoint
punt taż-żmien

unscheduled tumour assessments were moved to the nearest scheduled timepoint
analiżi tat- tumur mhux ipprogrammati tmexxew għall- eqreb punt ta ’ iprogrammat

mmr rates by specific timepoint are displayed graphically in figure 2.
ir-rati ta’ mmr skont il-punt taż-żmien speċifiku huma murija grafikament f’figura 2.

from this timepoint all patients were treated if pre- specified criteria were met.
minn dan il-punt ta’ żmien il-pazjenti kollha kienu ttrattati jekk jintlaħqu kriterji speċifikati minn qabel.

at each timepoint you will receive a 300 mg dose given as two injections of 150 mg.
f’kull perjodu ta’ żmien tingħata doża ta’ 300 mg mogħtija bħala żewġ injezzjonijiet ta’ 150 mg.

in fortacin-treated subjects, ielt and ipe scores increased at the first measured timepoint.
fis-suġġetti kkurati b’fortacin, il-punteġġi ielt u ipe żdiedu fl-ewwel punt ta’ żmien imkejjel.

quality of life in psoriatic arthritis patients was assessed at every timepoint using the disability index of the haq.
il-kwalità tal-ħajja f’pazjenti b’artrite psorjatika kienet evalwata f’kull punt ta’ żmien bl-użu tal-indiċi tad-diżabilità tal-haq.

a n reflects randomised patients; actual number of patients evaluable for each endpoint may vary by timepoint.
a n jirrifletti pazjenti randomised; numru attwali ta’ pazjenti li jistgħu jiġu evalwati għal kull mira finali jista’ jvarja skont il-punt taż-żmien.

in the infliximab group, the mean change in total modified vdh-s score remained below 0 at the week 54 timepoint.
fil-grupp fuq infliximab, il- medja tal-bidla fil-punteġġ totali modifikat ta’ vdh-s baqa’ taħt 0 sat-timepoint ta’ ġimgħa 54.

the day 3 timepoint was chosen since the pharmacokinetic exposure was maximum on that day in a previous 14-day multiple dose pharmacokinetic study.
il-punt ta’ ħin ta’ Ġurnata 3 intagħżel peress li l-esponiment farmakokinetiku kien l-ogħla f’din il-ġurnata fi studju farmakokinetiku preċedenti b’dożi multipli fuq medda ta’ 14-il ġurnata.

aclasta significantly decreased the incidence of one or more new vertebral fractures over three years and as early as the one year timepoint (see table 2).
aclasta naqqas b’mod sinifikanti l-inċidenza ta’ wieħed jew aktar fratturi ġodda fl-irkiekel fuq perjodu ta’ tliet snin u dan sa mill-ewwel sena li ttieħdet bħala timepoint (ara tabella 2).

there was essentially no difference in the detection of the presence or absence of osteomyelitis between the 1-2 hour timepoint and the 5-8 hour timepoint after injection.
ma kien hemm l-ebda differenza bejn 1-2 siegha u 5-8 sieghat ghad-dijanjosi ta’ infezzjoni.

cumulatively, there were 4 patients who experienced a viremic episode (hbv dna>400 copies/ml) at their last timepoint on tdf.
kumulattivament, kien hemm 4 pazjenti li kellhom episodju viremiku (dna tal-hbv ta’ > 400 kopja/ml) fl-aħħar punt ta’ żmien tagħhom fuq tenofovir disoproxil fumarate.

the 100 microgram dose peaked at 1 and 2 hours with a mean %id/g of 0.0018%/g ± 0.001%/g at each timepoint.
id-doża ta’ 100 mikrogramma laħqet il-massimu f’siegħa u f’sagħtejn b’ %id/g medju ta’ 0.0018%/g ± 0.001%/g f’kull punt ta’ ħin.

the disability index score was significantly improved at all timepoints in psoriatic arthritis patients treated with enbrel, relative to placebo (p < 0.001).
l- iskor ta ’ l- indiċi tad - diżabilità kien sinjifikament aħjar f’ kull punt ta ’ żmien f’ pazjenti bl- artrite psorjatika ikkurati b’ enbrel, relatat mal- plaċebo (p < 0. 001).